Newsroom
If you would like to be added to Volition's mailing list to receive press releases and other news, please submit this form:
|
VolitionRX Limited Issues 525,000 Shares to ValiRx; Final Requirement of Share Purchase Agreement
Singapore, December 9, 2011… VolitionRX Limited (VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, is pleased to announce that it will issue US$1,110,000 worth of shares of its common stock to AIM-listed company, ValiRx PLC. The share issuance is the final requirement of the Share Purchase Agreement dated 22 September 2010 (as amended on 9 June 2011) between ValiRx and Singapore Volition Pte Limited, a subsidiary of VolitionRX.
|
|
Read more...
|
|
VolitionRX Subsidiary Enters into its first Revenue-Generating Agreement to Profile Blood-Based Epigenetic Signatures
Singapore, November 15, 2011… VolitionRX Limited (“Volition”)(VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, is pleased to announce that its wholly owned subsidiary, HyperGenomics Pte Limited (“HyperGenomics”), has signed a contract which is expected to provide Volition with its first revenues. Volition has been commissioned to develop epigenetic profiling signatures from blood.
|
|
Read more...
|
|
Volition Names Clinical Evaluation Committee
Singapore, November 8, 2011… VolitionRX Limited (VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, is pleased to announce that it has named a Clinical Evaluation Management Committee. The committee will act as a semi-independent advisory board, guiding Volition’s clinical trial and validation strategy both for European CE Mark and American FDA approval processes.
|
|
Read more...
|
|
VolitionRX Limited Issues Update Letter to Shareholders
Singapore, October 31 2011… VolitionRX Limited (VNRX.OB) (“Volition” or the “Company”), a life sciences company focused on developing blood-based diagnostic tests, has published a letter to its shareholders from Cameron Reynolds, CEO. Please click through for the full letter.
|
|
Read more...
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
|
Page 5 of 10
|
